Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
NMRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.61 - $17.19
Previous CloseN/A
Volume2.95M
Average Volume (3M)529.81K
Market Cap
$246.16M
Enterprise Value-$79.06M
Total Cash (Recent Filing)$217.59M
Total Debt (Recent Filing)$510.00K
Price to Earnings (P/E)―
Beta2.26
Next Earnings
Oct 29, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding161,945,430
10 Day Avg. Volume381,764
30 Day Avg. Volume529,808
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.30
Forecast
1Y Price Target
$8.25Price Target Upside468.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Market ResponseNMRA's shares have increased significantly since the announcement of the new M4 PAM candidate, indicating market embrace of the news.
New Drug DevelopmentNMRA has introduced NMRA-861, a new M4 PAM candidate for schizophrenia and other neuropsychiatric disorders, which has advanced into the clinic.
Strategic FocusThe management revealed a new program targeting obesity with NMRA-215, a high brain entrant NLRP3 inhibitor, a mechanism that has shown promise.
Bears Say
Clinical Trial RisksThere is a high level of risk associated with the ongoing trials of navacaprant, and the recent trial modifications signify uncertainty in the success of future outcomes.
Stock Performance ConcernsThere is a belief that the stock will continue to underperform relative to the rest of the coverage into and around the phase 3 KOASTAL-2/KOASTAL-3 trial readouts, which are seen as inherently high risk.
Strategic DecisionsThe strategic decision to move into obesity treatments with NMRA-215 is questioned due to its early development stage, which will take time to fully derisk.
Neumora Therapeutics, Inc. News
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $0.61 and its highest was $17.19 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $246.16M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Oct 29, 2025 which is in 40 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.363 by $0.033.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -0.33.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 161,945,430 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.363. Following the earnings report the stock price went up 3.774%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NMRA
Neumora Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.25 (468.97% Upside)
$8.25 (468.97% Upside)
Blogger Sentiment
Bearish
NMRA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 774.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.43%
12-Months-Change
Fundamentals
Return on Equity
-89.37%
Trailing 12-Months
Asset Growth
-44.66%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
NMRA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a company with a strong pipeline and financial position, with significant upcoming clinical milestones that could create substantial value. However, the continued net loss and competitive challenges in the obesity market were noted as areas of concern.View all NMRA earnings summariesNMRA Stock 12 Month Forecast
Average Price Target
$8.25
▲(468.97% Upside)
Technical Analysis
Ownership Overview
25.08% Insiders
5.57% Mutual Funds
19.54% Other Institutional Investors
47.03% Public Companies and
Individual Investors